leisure time -WSS

leisure time

author：focus 2025-09-27 12:56:33 - browse：221

Photo of an arrangement of aspirin pills — Patrick Sison/AP

Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease, a small study out of Boston found.

The clinical trial, led by Tracey Simon of Massachusetts General Hospital and Harvard Medical School, compared two groups of patients with metabolic dysfunction-associated steatotic liver disease, or MASLD. One group was given baby aspirin daily for six months, while the other received a placebo pill. At the end of the study period, the aspirin group had reduced hepatic fat content while the placebo group had higher fat buildup.

MASLD (formerly known as non-alcoholic fatty liver disease) is a growing health threat, with 1 in 3 Americans having a troublesome amount of fat in their liver. The lipid buildup feeds into a toxic cycle of inflammation, tissue damage and, ultimately, irreversible scarring.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

WSS

Crowdfunding for unproven stem cell procedures spreads misinformation

FDA advisers back CAR

Why depression after traumatic brain injury is distinct

John Green on his newest strategy for fighting tuberculosis

Readout Newsletter: Bristol, Sangamo, Gilead, and more

How many hemophilia patients actually want gene therapy?

focus

leisure time

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Lupron, used to halt puberty in children, may cause lasting health problems

Novavax promises a turnaround & Lilly roils the obesity market

Vertex cell therapy lets patients with type 1 diabetes stop insulin

The cancer drug shortage isn’t new — and neither are the solutions

Medicare coverage of Wegovy, once blocked, now looks possible

Apple is now the first public company to be valued at $3 trillion

John Green on his newest strategy for fighting tuberculosis

Medical records are filled with copy

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Wikipedia

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Why depression after traumatic brain injury is distinct

Hubble vs. James Webb telescope images: See the difference

Dexcom's push to bring CGM to type 2 diabetes patients

UCLA team creates talking throat patch for voice disorders

Change Healthcare outage fallout shows need for new oversight

hotspot

explore

focus

hotspot